PMID- 19603344
OWN - NLM
STAT- MEDLINE
DCOM- 20110218
LR  - 20191210
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 50
IP  - 9
DP  - 2009 Sep
TI  - Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic 
      stem cell transplantation.
PG  - 1434-41
LID - 10.1080/10428190903085944 [doi]
AB  - Low CD34 + cell doses increase allograft-related mortality and very high doses 
      increase the risk of graft-versus-host disease. The optimum CD34 + cell dose 
      remains undefined. The effect of the CD34 + cell dose based on ideal weight was 
      analyzed in 130 patients with hematologic malignancies undergoing 
      reduced-intensity allogeneic blood cell transplantation in the context of factors 
      known to affect the outcome: chemosensitivity, donor age, lactate dehydrogenase 
      (LDH), human leukocyte antigen (HLA) match, performance status, and platelet 
      count. The survival of patients receiving >8 x 10(6)/kg CD34 + cells was not 
      significantly different from those receiving <6. The outcome of those receiving 
      6-8 x 10(6)/kg CD34 + cells was significantly better than the rest. This 
      superiority was confirmed in multivariable analysis. Among patients receiving 
      <or=8 x 10(6)/kg CD34 + cells, an increasing number of infused cells was 
      associated with higher overall survival in a continuous fashion (Risk ratio (RR) 
      0.8759; p = 0.045). Cell dose based on actual weight did not correlate with 
      survival. The number of CD34 + cells infused, a potentially modifiable factor, 
      affects survival after reduced-intensity allogeneic transplantation. We recommend 
      a CD34 + cell dose of 6-8 x 10(6) per kg ideal body weight to optimize outcome. 
      The possible adverse effect of higher cell doses (>8) needs further confirmation.
FAU - Mehta, Jayesh
AU  - Mehta J
AD  - The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, 
      Northwestern University, Chicago, IL, USA. j-mehta@northwestern.edu
FAU - Mehta, Jayesh
AU  - Mehta J
FAU - Frankfurt, Olga
AU  - Frankfurt O
FAU - Altman, Jessica
AU  - Altman J
FAU - Evens, Andrew
AU  - Evens A
FAU - Tallman, Martin
AU  - Tallman M
FAU - Gordon, Leo
AU  - Gordon L
FAU - Williams, Stephanie
AU  - Williams S
FAU - Winter, Jane
AU  - Winter J
FAU - Krishnamurthy, Jairam
AU  - Krishnamurthy J
FAU - Duffey, Sara
AU  - Duffey S
FAU - Singh, Veerpal
AU  - Singh V
FAU - Meagher, Richard
AU  - Meagher R
FAU - Grinblatt, David
AU  - Grinblatt D
FAU - Kaminer, Lynne
AU  - Kaminer L
FAU - Singhal, Seema
AU  - Singhal S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, CD34)
SB  - IM
CIN - Leuk Lymphoma. 2009 Sep;50(9):1395-6. PMID: 19672777
MH  - Adult
MH  - Aged
MH  - Antigens, CD34/*metabolism
MH  - Calibration
MH  - Cell Count
MH  - Female
MH  - Hematologic Neoplasms/*therapy
MH  - Hematopoietic Stem Cell Transplantation/adverse effects/*methods/*standards
MH  - Hematopoietic Stem Cells/*cytology/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Homologous
MH  - Young Adult
EDAT- 2009/07/16 09:00
MHDA- 2011/02/22 06:00
CRDT- 2009/07/16 09:00
PHST- 2009/07/16 09:00 [entrez]
PHST- 2009/07/16 09:00 [pubmed]
PHST- 2011/02/22 06:00 [medline]
AID - 913168541 [pii]
AID - 10.1080/10428190903085944 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2009 Sep;50(9):1434-41. doi: 10.1080/10428190903085944.